Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Diabetes Mellitus 2Vomiting 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostatic Neoplasms 1Premature Birth 1Pre-Eclampsia 1Polycystic Ovary Syndrome 1Parathyroid Neoplasms 1Neoplasms 1Medulloblastoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Leiomyosarcoma 1Hyperparathyroidism, Primary 1Hot Flashes 1HER2 IHC3+ Advanced Colorectal Cancer 1Erectile Dysfunction 1Cognitive Dysfunction 1Carcinoma, Renal Cell 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1regorafenib 1Trifluridine 1Tablets 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2 IHC3+ Advanced Colorectal Cancer × Tablets × Clear all
NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
142 enrolled
Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡